About ABT Molecular Imaging
ABT Molecular Imaging is a company based in Louisville (United States) founded in 2006 by Lynda Nutt and Ronald Nutt. ABT Molecular Imaging has raised $29.07 million across 11 funding rounds from investors including SWK Holdings, River Cities Capital and Mountain Group Partners. ABT Molecular Imaging operates in a competitive market with competitors including ImaginAb, AC Immune, APRINOIA, BioArctic and Blue Earth Diagnostics, among others.
- Headquarter Louisville, United States
- Founders Lynda Nutt, Ronald Nutt
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.07 M (USD)
in 11 rounds
-
Latest Funding Round
$10 M (USD), Series C
Oct 01, 2014
-
Investors
SWK Holdings
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ABT Molecular Imaging
ABT Molecular Imaging has successfully raised a total of $29.07M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $10 million completed in October 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ABT Molecular Imaging
ABT Molecular Imaging has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include SWK Holdings, River Cities Capital and Mountain Group Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital is directed toward life sciences and technology sectors.
|
Locked | Locked | Locked | |
|
Council Capital is focused on healthcare investment and support.
|
Locked | Locked | Locked |
Investor details for ABT Molecular Imaging
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ABT Molecular Imaging
Investment portfolio details for ABT Molecular Imaging
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ABT Molecular Imaging
Detailed financials for ABT Molecular Imaging
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abt Molecular Imaging Comparisons
Peer comparison for ABT Molecular Imaging
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ABT Molecular Imaging
ABT Molecular Imaging operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, AC Immune, APRINOIA, BioArctic and Blue Earth Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Disease-modifying treatments for neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Radioactive molecular imaging agents for cancer are developed.
|
|
| Locked | Locked | Locked |
Cancer diagnosis devices targeting VPAC1 receptors are developed.
|
Detailed competitors of ABT Molecular Imaging
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abt Molecular Imaging
Complete news archive for ABT Molecular Imaging
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABT Molecular Imaging
ABT Molecular Imaging was founded in 2006 and raised its 1st funding round 3 years after it was founded.
ABT Molecular Imaging is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.
ABT Molecular Imaging is a funded company, having raised a total of $29.07M across 11 funding rounds to date.
ABT Molecular Imaging was founded in 2006 in Louisville, United States, and operates in the medical imaging sector. Generators such as the BG-75 model are produced to create unit doses of positron emission tomography (PET) biomarkers at the point of use. Quality control tests are conducted for each dose, and records are maintained for every generation. Operations focus on supporting molecular imaging applications in healthcare settings.
ABT Molecular Imaging has 5 investors. Key investors include SWK Holdings, River Cities Capital, Mountain Group Partners, Council Capital, and Intersouth Partners.